frog, I think you answered your own question w/
..."Does Beth Isreal think that DNAP is the best choice to finish the development and then market their drug?"
That would be the logical conclusion, and I doubt looking for other discrediting reasons very practical, unless surmising for/or submitting missing info, in depreciation be your part to play.
Hey, just my thoughts, and imho, and would be ginning on a gurney if I had to take the journey.
Easy